ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / ATNM / insiders
BMEA (30) MREO (37) ELTX (28) HOWL (42) ⌘ Pro Terminal →

Actinium Pharmaceuticals Inc. (Delaware) (ATNM) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$1.43 -3.38% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.42

Actinium Pharmaceuticals Inc. (Delaware) (ATNM) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • SELL / AVOID Cap $46.5M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ATNM Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ATNM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Actinium Pharmaceuticals Inc. (Delaware) (NYSE: ATNM) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $1.43 (-3.38% 1D, market cap $46.5M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 14/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, ATNM ranks #413 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ATNM compare to BMEA and MREO in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ATNM carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BMEA (Biomea Fusion Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $46.4M) and MREO (Mereo BioPharma Group plc) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $46.2M). Among the 5-stock peer group, ATNM leads on earnings multiple (N/A) while ATNM leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ATNM?
▼

Per ATNM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001388320), Actinium Pharmaceuticals Inc. (Delaware) generated $90.0K in revenue (-99.9% YoY), -$33.9M in net income, and -$24.7M in free cash flow against $51.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.42 (-0.80%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-6.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D-
025507510043
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D
Cash (8)Whales (14)SEC (8)Macro (10)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-7% Base Target
$2 Bull$1 Base$1 Bear
📬 FREE ATNM RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ATNM)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (43/100 Composite)
🔍 WHY ATNM SCORES 43/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+14/20 pts (33% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (23% of score)

FRED Regime × Technicals: 70% of 52W Range • RSI-14 at 59.7 (BULLISH MOMENTUM)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
35
Grade E$1.00+40% Next Q
Q2 (-2Q)
38
Grade E$1.40+1.4% Next Q
Q3 (-1Q)
40
Grade D$1.42+0.7% Next Q
Current
43
Grade D-$1.43-6.7% Hist 90D α
Trajectory: E (35) → D- (43)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ATNM Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ATNM currently carries a cautious 43/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.21) and Max Pain ($1.50) forces dealer call-delta covering toward $1.81.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ATNM• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ATNM Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 43%NO 57%Trade / Inspect Odds →
SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

ATNM Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →
▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (ATNM)

No recent open-market Form 4 cluster sales or emergency dumps flagged on ATNM. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ATNM)

  • ✓Walkthrough of ATNM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
ATNM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +19.17%📐 HORIZONTAL RANGE
2026-11-03O $1.53H $1.53L $1.43C $1.43VOL 157.7K
RES: $1.73SUP: $0.94SMA50: $1.21SMA200: $1.12
$1.72$1.46$1.19$0.92$0.66RES $1.73SUP $0.94$1.432026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ATNM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ATNM Butterfly Map → + Track ATNM →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -99.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ATNM today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ATNM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ATNM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ATNM)

Health Care Rank #413 of 1015 ⚔️ BMEA vs ATNM Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ATNM vs. BMEA, MREO, ELTX, HOWL)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Actinium Pharmaceuticals Inc. (Delaware) (ATNM) ranks #413 by composite RQD confidence (43/100, grade D-) and #755 by equity capitalization ($46.5M). Within this direct 5-issuer industry benchmark cohort, ATNM leads on earnings valuation at N/A trailing P/E, while ATNM leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. ATNM currently leads its immediate peer cohort in composite quantitative strength at 43/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ATNM ACTIVE
Actinium Pharmaceuticals Inc. (Delaware)
D- 43/100 — — -35.0% -3.38% $46.5M Benchmark Subject
BMEA
Biomea Fusion Inc.
E 30/100 — — -35.0% +3.19% $46.4M /bmea-vs-atnm →
MREO
Mereo BioPharma Group plc
D- 37/100 — — -35.0% +0.17% $46.2M /mreo-vs-atnm →
ELTX
Elicio Therapeutics Inc.
E 28/100 — — -35.0% -5.36% $45.5M /eltx-vs-atnm →
HOWL
Werewolf Therapeutics Inc.
D- 42/100 — — -35.0% +6.48% $47.9M /howl-vs-atnm →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001388320 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Actinium Pharmaceuticals Inc. (Delaware) (ATNM) reported GAAP revenue of $90.0K (-99.9% vs. FY2024 revenue of $117.9M , and +11.1% cumulative change since FY2023) , GAAP net income of -$33.9M, operating cash flow of -$24.6M, and free cash flow of -$24.7M (+25.4% YoY). On the balance sheet, ATNM closed FY2025 with $51.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $90.0K -$33.9M -$24.6M -$24.7M $51.8M —
FY2024 (FY) 2024-12-31 $117.9M -$38.2M -$33.1M -$33.1M $76.9M —
FY2023 (FY) 2023-12-31 $81.0K -$48.8M -$47.3M -$47.3M — —

3. ATNM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ATNM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Actinium Pharmaceuticals Inc. (Delaware) (NYSE: ATNM) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $1.43 (-3.38% 1D, market cap $46.5M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 14/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, ATNM ranks #413 in composite RQD confidence.

How does ATNM compare to BMEA and MREO in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ATNM carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BMEA (Biomea Fusion Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $46.4M) and MREO (Mereo BioPharma Group plc) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $46.2M). Among the 5-stock peer group, ATNM leads on earnings multiple (N/A) while ATNM leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ATNM?

Per ATNM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001388320), Actinium Pharmaceuticals Inc. (Delaware) generated $90.0K in revenue (-99.9% YoY), -$33.9M in net income, and -$24.7M in free cash flow against $51.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ATNM trading relative to its 50-day, 200-day, and 52-week technical levels?

ATNM last traded at $1.43 (-3.38% on volume of 104,586 shares), positioning the stock +18.18% above its 50-day simple moving average ($1.21) and +27.68% above its 200-day simple moving average ($1.12). Across its 52-week range of $0.74 to $1.72, ATNM sits at the 70.4% percentile with a 14-day RSI of 59.7 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($1.25 to $1.61).

Direct Sub-Reports: ATNM RQD Cockpit ATNM 12M Forecast ATNM Earnings & Move ATNM Dividends & DRIP ATNM Insiders & 13F ATNM Whale Options ATNM Profit Sankey ATNM News & Why
ROARABLE RATING BRIEF • RQD 43/100 (D-) ✓ SEC XBRL & RQD VERIFIED

ATNM — Actinium Pharmaceuticals Inc. (Delaware): What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Actinium Pharmaceuticals Inc. (Delaware) (ATNM) earns a live Roarable RQD composite score of 43/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $1.43 (-3.38% 1D, market capitalization $46.5M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of -60.0%, and free cash flow yield of —.
  • Whale 13F & Options Flow (14/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Actinium Pharmaceuticals Inc. (Delaware) (ATNM) is a NYSE-listed issuer. It operates in the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry. Reported revenue appears in the SEC financials at $0.1M for FY 2025 and — for FY 2024, which indicates minimal commercial revenue in the periods provided.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Actinium Pharmaceuticals Inc. (Delaware) (ATNM) reported $90.0K in annual revenue (up from $117.9M in FY2024, -99.9% YoY) and -$33.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($81.0K revenue, -$48.8M net income) through FY2025, ATNM scaled operating cash flow to -$24.6M and free cash flow to -$24.7M, backed by $51.8M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 43/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 14/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 14/20, sustained execution supports upside toward the upper end of the $0.74 – $1.72 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Sector classification is Health Care and industry is Biotechnology: Pharmaceutical Preparations. No upstream or downstream dependencies, sector correlations, or second-order bottlenecks are identified in source data.

  • Key Question #1: Can ATNM sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $90.0K and free cash flow of -$24.7M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is ATNM's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ATNM Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Actinium Pharmaceuticals Inc. (Delaware) (ATNM) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ATNM Debate Forum (3) ↓
🟡 MARKET WIRE Benzinga • 11d ago
Actinium Pharma To Present First‑In‑Human Phase 1 Study Of ATNM‑400, HER3-Targeted, Non-PSMA Radiotherapy, In Metastatic Castration‑Resistant Prostate Cancer, At ESMO Congress 2026

First‑in‑human Phase 1 study evaluates HER3‑targeted ATNM‑400 in metastatic castration‑resistant prostate cancer population, including patients with and without prior PSMA‑directed therapy HER3‑targeted alpha

Read Full Source ↗
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ATNM Bull vs. Bear Conversation Board — What's Your Call at $1.43?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ATNM 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ATNM:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $1.91 (+29.1%)
📌 Pinned Debate

Institutional accumulation and options positioning score 14/20, the strongest pillar in the RQD rating.

The street is overcomplicating Actinium Pharmaceuticals Inc. (Delaware) (ATNM). Institutional accumulation and options positioning score 14/20, the strongest pillar in the RQD rating.. With an RQD score of 43/100 (D-) and Forensic Balance Sheet at 8/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $1.60.

ArenaChamp_24 🐂 BULL

@RiskArb_Desk Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH 🎯 Target: $1.26 (-14.9%)
Spot @ $1.48

Negative ROIC of -35% and 0% FCF yield, with FY 2025 free cash flow of -$24.7M, show the company is not self-funding.

Negative ROIC of -35% and 0% FCF yield, with FY 2025 free cash flow of -$24.7M, show the company is not self-funding.. Look at the math on ATNM: paying current EV/EBITDA multiples for -35.0% ROIC and -60.0% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $1.30 before getting long.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%